Nitric oxide (NO) is a potent biological mediator, and has a regulatory role in a wide variety of cellular and tissue functions. In the upper and lower airways, NO has been suggested to be involved in different functions with regulatory, protective, defensive or damaging effects. It is obvious that NO plays an important role in host defense, and is liberated in the nose and the paranasal sinuses. This review aims to highlight some aspects of the origin and function of NO in airway diseases, such as allergic rhinitis, chronic rhinosinusitis with and without nasal polyps, primary ciliary dyskinesia, and cystic fibrosis. In conclusion, NO measurement may be a promising noninvasive diagnostic marker for airway pathologies.

1.
Murad F, Mittal CK, Arnold WP, Katsuki S, Kimura H: Guanylate cyclase: activation by azide, nitro compounds, nitric oxide, and hydroxyl radical and inhibition by hemoglobin and myoglobin. Adv Cyclic Nucleotide Res 1978;9:145–158.
2.
Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373–376.
3.
Ignarro L, Buga G, Wood K, Byrns R, Chaudhuri G: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265–9269.
4.
Palmer RM, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524–526.
5.
Gustafsson I, Leone A, Persson M, Wiklund N, Moncada S: Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun 1991;181:852–857.
6.
Alving K, Weitzberg E, Lundberg JM: Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 1993;6:1368–1370.
7.
Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002–2012.
8.
Nathan C, Xie QW: Nitric oxide synthases: roles, tolls, and controls. Cell 1994;78:915–918.
9.
Kelm M: Nitric oxide metabolism and breakdown. Biochim Biophys Acta 1999;1411:273–289.
10.
Nathan C: Nitric oxide as a secretory product of mammalian cells. FASEB J 1992;6:3051–3064.
11.
Djupesland P, Chatkin J, Qian W: Nitric oxide in the nasal airway: a new dimension in otorhinolaryngology. Am J Otolaryngol 2001;22:19–32.
12.
Förstermann U, Closs E: Nitric oxide synthase isoenzymes: characterisation, purification, molecular cloning, and functions. Hypertension 1994;23:1121–1131.
13.
Nathan C: Inducible nitric oxide synthase: what difference does it make? J Clin Invest 1997;100:2417–2423.
14.
Nathan C, Xie QW: Regulation of biosynthesis of nitric oxide. J Biol Chem 1994;269:13725–13728.
15.
Hibbs JB Jr: Infection and nitric oxide. J Infect Dis 2002;18(suppl 1):S9–S17.
16.
Rimele TJ, Sturm RJ, Adams LM, Henry DE, Heaslip RJ, Weichman BM, Grimes D: Interaction of neutrophils with vascular smooth muscle: identification of a neutrophil-derived relaxing factor. J Pharmacol Exp Ther 1988;245:102–111.
17.
Jorens PG, Van Overveld FJ, Bult H, Vermeire PA, Herman AG: L-Arginine-dependent production of nitrogen oxides by rat pulmonary macrophages. Eur J Pharmacol 1991;200:205–209.
18.
Lundberg JO, Weitzberg E, Rinder J, Rudehill A, Jansson O, Wiklund NP, et al: Calcium-independent and steroid-resistant nitric oxide synthase activity in human paranasal sinus mucosa. Eur Respir J 1996;9:1344–1347.
19.
Maniscalco M, Sofia M, Pelaia G: Nitric oxide in upper airways inflammatory diseases. Inflamm Res 2007;56:58–69.
20.
Kharitonov S, Alving K, Barnes PJ: Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. Eur Respir J 1997;10:1683–1693.
21.
Lundberg J, Rinder J, Weitzberg E, Lundberg JM, Alving K: Nasally exhaled nitric oxide in humans originates mainly in the paranasal sinuses. Acta Physiol Scand 1994;152:431–432.
22.
Lundberg JO, Farkas-Szallasi T, Weitzberg E, Rinder J, Lidholm J, Anggaard A, Hökfelt T, Lundberg JM, Alving K: High nitric oxide production in human paranasal sinuses. Nat Med 1995;1:370–373.
23.
Kimberly B, Nejadnik B, Giraud GD: Nasal contribution to exhaled nitric oxide at rest and during breathholding in humans. Am J Resp Crit Care Med 1996;153:829–836.
24.
Dillon WC, Hampl V, Shultz PJ, Rubins JB, Archer SL: Origins of breath nitric oxide in humans. Chest 1996;110:930–938.
25.
Lundberg J, Weitzberg E, Nordvall S: Primarily nasal origin of exhaled nitric oxide and absence in Katagener’s syndrome. Eur Resp J 1994;7:1501–1504.
26.
Schedin U, Frostell C, Persson MG, Jakobsson J, Andersson G, Gustafsson LE: Contribution from upper and lower airways to exhaled endogenous nitric oxide in humans. Acta Anaesthesiol Scand 1995;39:327–332.
27.
Kramer MF, Olzowy B, Bihler A, de la Motte D, Nowak D, Jorres RA, Dressel H: Exhaled and nasal nitric oxide in laryngectomized patients. BMC Pulm Med 2010;10:4.
28.
Lundberg JO, Weitzberg E: Nasal nitric oxide in man. Thorax 1999;54:947–952.
29.
Haight J, Djupesland P, Qjan W, Chatkin J, Furlott H, Irish H: Does nasal nitric oxide come from the sinuses? Otolaryngol 1999;28:197–204.
30.
Kawamoto H, Takeno S, Yajin K: Increased expression of inducible nitric oxide synthase in nasal epithelial cells in patients with allergic rhinitis. Laryngoscope 1999;109:2015–2020.
31.
Kawamoto H, Takumida M, Takeno S, Watanabe H, Fukushima N, Yajin K: Localization of nitric oxide synthase in human nasal mucosa with nasal allergy. Acta Otolaryngol Suppl 1998;539:65–70.
32.
Giannessi F, Fattori B, Ursino F, Giambelluca MA, Soldani P, Scavuzzo MC, Ruffoli R: Ultrastructural and ultracytochemical study of the human nasal respiratory epithelium in vasomotor rhinitis. Acta Otolaryngol 2003;123:943–949.
33.
Kirihene RK, Rees G, Wormald PJ: The influence of the size of the maxillary sinus ostium on the nasal and sinus nitric oxide levels. Am J Rhinol 2002;16:261–264.
34.
Croen KD: Evidence for antiviral effect of nitric oxide: inhibition of herpes simplex virus type 1 replication. J Clin Invest 1993;91:2446–2452.
35.
Mancinelli RL, McKay CP: Effects of nitric oxide and nitrogen dioxide on bacterial growth. Appl Environ Microbiol 1983;46:198–202.
36.
Jain B, Rubinstein I, Robbins RA, Leise KL, Sisson JH: Modulation of airway epithelial cell ciliary beat frequency by nitric oxide. Biochem Biophys Res Commun 1993;191:83–88.
37.
Alberty J, Stoll W, Rudack C: The effect of endogenous nitric oxide on mechanical ciliostimulation of human nasal mucosa. Clin Exp Allergy 2006;36:1254–1259.
38.
Runer T, Lindberg S: Effects of nitric oxide on blood flow and mucociliary activity in the human nose. Ann Otol Rhinol Laryngol 1998;107:40–46.
39.
Lundberg Jo, Lundberg JM, Settergreen G, Alving K, Weitzberg E: Nitric oxide, produced in the upper airways, may act in an ‘aerocrine’ fashion to enhance pulmonary oxygen uptake in humans. Acta Physiol Scand 1995;155:467–468.
40.
Lundberg JO, Settergren G, Gelinder S, Lundberg JM, Alving K, Weitzberg E: Inhalation of nasally derived nitric oxide modulates pulmonary function in humans. Acta Physiol Scand 1996;158:343–347.
41.
Gerlach H, Rossaint R, Pappert D, Falke KJ: Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Eur J Clin Invest 1993;23:499–502.
42.
Puybasset L, Rouby JJ, Mourgeon E, Stewart TE, Cluzel P, Arthaud M, Poète P, Bodin L, Korinek AM, Viars P: Inhaled nitric oxide in acute respiratory failure: dose-response curves. Intensive Care Med 1994;20:319–327.
43.
Busch T, Kuhlen R, Knorr M, Kelly K, Lewandowski K, Rossaint R, Falke KJ, Gerlach H: Nasal, pulmonary and autoinhaled nitric oxide at rest and during moderate exercise. Intensive Care Med 2000;26:391–399.
44.
Gerlach H, Rossaint R, Pappert D, Knorr M, Falke KJ: Autoinhalation of nitric oxide after endogenous synthesis in nasopharynx. Lancet 1994;343:518–519.
45.
Tornberg DC, Marteus H, Schedin U, Alving K, Lundberg JO, Weitzberg E: Nasal and oral contribution to inhaled and exhaled nitric oxide: a study in tracheotomized patients. Eur Respir J 2002;19:859–864.
46.
Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM: Inhaled nitric oxide: a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991;83:2038–2047.
47.
Roberts JD Jr, Fineman JR, Morin FC 3rd, Shaul PW, Rimar S, Schreiber MD, Polin RA, Zwass MS, Zayek MM, Gross I, Heymann MA, Zapol WM: Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med 1997;336:605–610.
48.
Alving K, Janson C, Nordvall L: Performance of a new hand-held device for exhaled nitric oxide measurement in adults and children. Respir Res 2006;7:67.
49.
Menzies D, Nair A, Lipworth BJ: Portable exhaled nitric oxide measurement: comparison with the ‘gold standard’ technique. Chest 2007;131:410–414.
50.
Khalili B, Boggs PB, Bahna SL: Reliability of a new hand-held device for the measurement of exhaled nitric oxide. Allergy 2007;62:1171–1174.
51.
Olin A, Bake B: Fraction of exhaled nitric oxide at 50 ml/s: reference values for adult lifelong never-smokers. Chest 2007;131:1852–1856.
52.
Struben VM, Wieringa MH, Mantingh CJ, Bommeljé C, Don M, Feenstra L, de Jongste JC: Nasal NO: normal values in children age 6 through to 17 years. Eur Respir J 2005;26:453–457.
53.
Daya H, Qian W, McClean P, Haight J, Zamel N, Papsin BC, Forte V: Nasal nitric oxide in children: a novel measurement technique and normal values. Laryngoscope 2002;112:1831–1835.
54.
Cobos Barroso N, Reverté Bover C, Gartner S, Liñán Cortés S, Quintó Domech L: Exhaled and nasal nitric oxide in normal and asthmatic children (in Spanish). An Esp Pediatr 1998;49:241–247.
55.
Balfour-Lynn IM, Laverty A, Dinwiddie R: Reduced upper airway nitric oxide in cystic fibrosis. Arch Dis Child 1996;75:319–322.
56.
Kharitonov SA, Chung KF, Evans D, O’Connor BJ, Barnes PJ: Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. Am J Respir Crit Care Med 1996;153:1773–1780.
57.
Guilemany JM, García-Piñero A, Alobid I, Cardelús S, Centellas S, Bartra J, Valero A, Picado C, Mullol J: Persistent allergic rhinitis has a moderate impact on the sense of smell, depending on both nasal congestion and inflammation. Laryngoscope 2009;119:233–238.
58.
Arnal J: Nasal nitric oxide is increased in allergic rhinitis. Clin Exp Allergy 1997;27:358–362.
59.
Henriksen A, Sue-Chu M, Holmen T, Langhammer A, Bjermer L: Exhaled and nasal NO levels in allergic rhinitis: relation to sensitization, pollen season and bronchial hyperresponsiveness. Eur Respir J 1999;13:301–306.
60.
Kharitonov S: Nasal nitric oxide is increased in patients with asthma and allergic rhinitis and may be modulated by nasal glucocorticoids. Allergy Clin Immunol 1997;99:58–64.
61.
Martin U, Bryden K, Devoy M, Howarth P: Increased levels of exhaled nitric oxide during nasal and oral breathing in subjects with seasonal rhinitis. J Allergy Clin Immunol 1996;97:768–772.
62.
Takeno S, Osada R, Furukido K, Chen JH, Yajin K: Increased nitric oxide production in nasal epithelial cells from allergic patients – RT-PCR analysis and direct imaging by a fluorescence indicator: DAF-2 DA. Clin Exp Allergy 2001;31:881–888.
63.
Sato M, Fukuyama M: Increased nitric oxide in nasal lavage fluid and nitrotyrosine formation in nasal mucosa – indices for severe perennial nasal allergy. Clin Exp Allergy 1998;28:597–605.
64.
Palm JP, Alving K, Lundberg JO: Characterization of airway nitric oxide in allergic rhinitis: the effect of intranasal administration of L-NAME. Allergy 2003;58:885–892.
65.
Maniscalco M, Sofia M, Carratu L, Higenbottam T: Effect of nitric oxide inhibition on nasal airway resistance after nasal allergen challenge in allergic rhinitis. Eur J Clin Invest 2001;31:462–466.
66.
Valero A, Serrano C, Valera JL, Barberá A, Torrego A, Mullol J, Picado C: Nasal and bronchial response to exercise in patients with asthma and rhinitis: the role of nitric oxide. Allergy 2005;60:1126–1131.
67.
Meurs H, Hamer MA, Pethe S, Vadon-Le Goff S, Boucher JL, Zaagsma J: Modulation of cholinergic airway reactivity and nitric oxide production by endogenous arginase activity. Br J Pharmacol 2000;130:1793–1798.
68.
Chicoine LG, Paffett ML, Young TL, Nelin LD: Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol 2004;287:L60–L68.
69.
Maarsingh H, Leusink J, Bos IS, Zaagsma J, Meurs H: Arginase strongly impairs neuronal nitric oxide-mediated airway smooth muscle relaxation in allergic asthma. Respir Res 2006;7:6.
70.
Colantonio D, Brouillette L, Parikh A, Scadding GK: Paradoxical low nasal nitric oxide in nasal polyposis. Clin Exp Allergy 2002;32:698–701.
71.
Guilemany J, Angrill J, Alobid I: United airways again: high prevalence of rhinosinusitis and nasal polyps in bronchiectasis. Allergy 2009;64:790–797.
72.
Gilain L, Bedu M, Jouaville L, Guichard C, Advenier D, Mom T, Laurent S, Caillaud D: Analysis of nasal and exhaled nitric oxide concentration in nasal polyposis (in French). Ann Otolaryngol Chir Cervicofac 2002;119:234–242.
73.
Cekin E, Ipcioglu OM, Erkul BE, Kapucu B, Ozcan O, Cincik H, Gungor A: The association of oxidative stress and nasal polyposis. J Int Med Res 2009;37:325–330.
74.
Prieto L, Seijas T, Gutierrez V, Uixera S, Bruno L, Lopez R: Exhaled nitric oxide levels and airway responsiveness to adenosine 5′-monophosphate in subjects with nasal polyposis. Int Arch Allergy Immunol 2004;134:303–309.
75.
Ragab SM, Lund VJ, Saleh HA, Scadding G: Nasal nitric oxide in objective evaluation of chronic rhinosinusitis therapy. Allergy 2006;61:717–724.
76.
Arnal J, Flores P, Rami J, Murris-Espin M, Bremont F, Pasto I: Nasal nitric oxide concentration in paranasal sinus inflammatory diseases. Eur Respir J 1999;13:307–312.
77.
Delclaux C, Malinvaud D, Chevalier-Bidaud B, Callens E, Mahut B, Bonfils P: Nitric oxide evaluation in upper and lower respiratory tracts in nasal polyposis. Clin Exp Allergy 2008;38:1140–1147.
78.
Lindberg S, Cervin A, Runer T: Nitric oxide (NO) production in the upper airways is decreased in chronic sinusitis. Acta Otolaryngol 1997;117:113–117.
79.
Deja M, Busch T, Bachmann S, Riskowski K, Campean V, Wiedmann B, Schwabe M, Hell B, Pfeilschifter J, Falke KJ, Lewandowski K: Reduced nitric oxide in sinus epithelium of patients with radiologic maxillary sinusitis and sepsis. Am J Respir Crit Care Med 2003;168:281–286.
80.
Baraldi E, Azzolin NM, Biban P, Zacchello F: Effect of antibiotic therapy on nasal nitric oxide concentration in children with acute sinusitis. Am J Respir Crit Care Med 1997;155:1680–1683.
81.
Degano B, Genestal M, Serrano E, Rami J, Arnal JF: Effect of treatment on maxillary sinus and nasal nitric oxide concentrations in patients with nosocomial maxillary sinusitis. Chest 2005;128:1699–1705.
82.
Min Y, Lee C, Rhee C: Increased expression of IL-4, IL-5, IFN-gamma, IL-6, IL-8 and TGF-beta mRNAs in maxillary mucosa of patients with chronic sinusitis. Am J Rhinol 1999;13:339–343.
83.
Zamora R, Vodovotz Y, Billiar TR: Inducible nitric oxide synthase and inflammatory diseases. Mol Med 2000;6:347–373.
84.
Lundberg JO, Maniscalco M, Sofia M, Lundblad L, Weitzberg E: Humming, nitric oxide, and paranasal sinus obstruction. JAMA 2003;289:302–303.
85.
Naraghi M, Deroee AF, Ebrahimkhani M, Kiani S, Dehpour A: Nitric oxide: a new concept in chronic sinusitis pathogenesis. Am J Otolaryngol 2007;28:334–337.
86.
Deroe A, Naraghi M, Sontou AF, Ebrahimkhani MR, Dehpour AR: Nitric oxide metabolites as biomarkers for follow-up after chronic rhinosinusitis surgery. Am J Rhinol Allergy 2009;23:159–161.
87.
Bush A: Primary ciliary dyskinesia. Acta Otorhinolaryngol Belg 2000;54:317–324.
88.
Grasemann H, Gartig S, Wiesemann H: Effect of L-arginine infusion on airway NO in cystic fibrosis and primary ciliary dyskinesia syndrome. Eur Respir J 1999;13:114–118.
89.
Karadag B, James AJ, Gultekin E, Wilson NM, Bush A: Nasal and lower airway level of nitric oxide in children with primary ciliary dyskinesia. Eur Respir J 1999;13:1402–1405.
90.
Wodehouse T: Nasal nitric oxide measurements for the screening of primary ciliary dyskinesia. Eur Respir J 2003;21:43–47.
91.
Horvath I, Loukides S, Wodehouse T, Csiszer E, Cole PJ, Kharitonov SA, Barnes PJ: Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels in bronchiectatic patients with and without primary ciliary dyskinesia. Thorax 2003;58:68–72.
92.
Csoma Z, Bush A, Wilson NM: Nitric oxide metabolites are not reduced in exhaled breath condensate of patients with primary ciliary dyskinesia. Chest 2003;124:633–638.
93.
Narang I, Ersu R, Wilson NM, Bush A: Nitric oxide in chronic airway inflammation in children: diagnostic use and pathophysiological significance. Thorax 2002;57:586–589.
94.
Noone PG, Leigh MW, Sannuti A, Minnix SL, Carson JL, Hazucha M, Zariwala MA, Knowles MR: Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004;169:459–467.
95.
Corbelli R, Bringolf-Isler B, Amacher A, Sasse B, Spycher M, Hammer J: Nasal nitric oxide measurements to screen children for primary ciliary dyskinesia. Chest 2004;126:1054–1059.
96.
Mahut B, Escudier E, de Blic J, Zerah-Lancner F, Coste A, Harf A, Delclaux C: Impairment of nitric oxide output of conducting airways in primary ciliary dyskinesia. Pediatr Pulmonol 2006;41:158–163.
97.
Scadding G, Scadding K: Update on the use of nitric oxide as a non-invasive measure of airways inflammation. Rhinology 2009;47:115–120.
98.
Runner T, Cervin A, Lindberg S: Nitric oxide is a regulator of mucociliary activity in the upper respiratory tract. Otolaryngol Head Neck Surg 1998;119:278–287.
99.
Lindberg S, Cervin A, Runer T: Low levels of nasal nitric oxide (NO) correlate to impaired mucociliary function in the upper airways. Acta Otolaryngol 1997;117:728–734.
100.
Loukides S, Kharitonov S, Wodehouse T, Cole PJ, Barnes PJ: Effect of arginine on mucociliary function in primary ciliary dyskinesia. Lancet 1998;352:371–372.
101.
Jeganathan D, Chodhari R, Meeks M, Faeroe O, Smyth D, Nielsen K, Amirav I, Luder AS, Bisgaard H, Gardiner RM, Chung EM, Mitchison HM: Loci for primary ciliary dyskinesia map to chromosome 16p12.1–12.2 and 15q13.1–15.1 in Faroe Islands and Israeli Druze genetic isolates. J Med Genet 2004;41:233–240.
102.
Escudier E, Duquesnoy P, Papon JF, Amselem S: Ciliary defects and genetics of primary ciliary dyskinesia. Paediatr Respir Rev 2009;10:51–54.
103.
Buchwalow IB, Minin EA, Muller FU, Lewin G, Samoilova VE, Schmitz W, Wellner M, Hasselblatt M, Punkt K, Müller-Werdan U, Demus U, Slezak J, Koehler G, Boecker W: Nitric oxide synthase in muscular dystrophies: a re-evaluation. Acta Neuropathol 2006;111:579–588.
104.
Grasemann H, Michler E: Decreased concentrations of exhaled nitric oxide (NO) in patients with cystic fibrosis. Ped Pulmol 1997;24:173–177.
105.
Zheng S, Xu W, Bose S, Banerjee AK, Haque SJ, Erzurum SC: Impaired nitric oxide synthase-2 signaling pathway in cystic fibrosis airway epithelium. Am J Physiol Lung Cell Mol Physiol 2004;287:L374–L381.
106.
Kelley T, Drumm M: Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest 1998;102:1200–1207.
107.
Shori DK, Dormer RL, Goodchild MC, McPherson MA: Defective phosphorylation of a calmodulin-binding protein in cystic-fibrosis submandibular glands. Biochem J 1989;263:613–616.
108.
Grasemann H, Ratjen F: Cystic fibrosis lung disease: the role of nitric oxide. Pediatr Pulmonol 1999;28:442–448.
109.
Grasemann H, Storm van’s Gravesande K, Buscher R, Knauer N, Silverman ES, Palmer LJ, Drazen JM, Ratjen F: Endothelial nitric oxide synthase variants in cystic fibrosis lung disease. Am J Respir Crit Care Med 2003;167:390–394.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.